Johnson & Johnson (JNJ)vsInnovative Eyewear Inc. (LUCY)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
LUCY
Innovative Eyewear Inc.
$1.05
+0.96%
HEALTHCARE · Cap: $6.49M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 3620218% more annual revenue ($96.36B vs $2.66M). JNJ leads profitability with a 21.8% profit margin vs -285.2%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
LUCY
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Margin of Safety
+39.2%
Fair Value
$1.81
Current Price
$1.05
$0.76 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Revenue surging 39.0% year-over-year
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -83.6% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : LUCY
The strongest argument for LUCY centers on Price/Book, Revenue Growth. Revenue growth of 39.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : LUCY
The primary concerns for LUCY are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while LUCY is a hypergrowth play — different risk/reward profiles.
LUCY carries more volatility with a beta of 3.06 — expect wider price swings.
LUCY is growing revenue faster at 39.0% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 36/100), backed by strong 21.8% margins. LUCY offers better value entry with a 39.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Innovative Eyewear Inc.
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Innovative Eyewear Inc. (LUCY) is a pioneering player in the smart eyewear sector, skillfully merging advanced technology with modern aesthetics to meet the needs of tech-savvy consumers. Its flagship line, Lucyd, stands out by integrating audio features and connectivity into stylish eyewear, thus providing both versatility and fashion. With a strong focus on innovation and enhancing user experiences, the company is well-positioned to harness the growing demand for multifunctional wearables, indicating significant growth potential in the rapidly evolving eyewear market. As trends shift towards smart solutions, LUCY's strategic approach positions it favorably for long-term success.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?